2015 News Releases

Keyword Search
 
2018 | 2017 | 2016 | 2015 | 2014
DateTitle 
12/16/15Merus Appoints Hui Liu as Chief Business Officer
Novartis Oncology’s Former Global Head of Business Development and Licensing Joins Immuno-oncology Biotech Company Utrecht, The Netherlands, December 16, 2015 — Merus B.V., a clinical-stage immuno-oncology company developing innovative bispecific antibody therapeutics, today announced the appointment of Hui Liu, Ph.D., as Chief Business Officer, effective December 16, 2015.  Liu joins Merus from Novartis Oncology, where he headed global business development and licensing ef... 
Printer Friendly Version
11/03/15Merus announces final Ruling in inequitable conduct case against Regeneron
Court Further Rules That Regeneron Engaged in Affirmative Egregious MisconductUTRECHT, The Netherlands, Nov. 3, 2015 (GLOBE NEWSWIRE) — Merus B.V., a clinical-stage immuno-oncology company developing innovative bispecific antibody therapeutics, today announced that the U.S. District Court for the Southern District of New York has issued its full written opinion in the Company’s inequitable conduct case against Regeneron Pharmaceuticals, Inc. On August 6, 2015, Judge Katherine B. Forrest ruled th... 
Printer Friendly Version
08/26/15Merus enters into € 72.8 million series C financing led by Sofinnova Ventures and Novo A/S
Utrecht, The Netherlands., August 26, 2015 – Merus B.V., a clinical-stage immuno-oncology company developing innovative bispecific antibody therapeutics, today announced that it has entered into an agreement with investors for the sale of up to € 72.8 million ($80.5 million) of Series C preferred shares and consummated the first tranche under the agreement. New investors include Sofinnova Ventures and Novo A/S as the co-leads, along with RA Capital Healthcare Fund, Rock Springs Capital, Tek... 
Printer Friendly Version
08/10/15Merus Prevails in Inequitable Conduct Case Against Regeneron
• Court ruling further strengthens Merus’ freedom to operate in using transgenic mice for therapeutic human antibodies Utrecht, The Netherlands, August 10, 2015 — Merus, a leader in developing best-in-class bispecific antibody therapeutics to treat cancer patients, today announced that it won its inequitable conduct trial against Regeneron. In a decision issued on Thursday, August 6, Judge Katherine B. Forrest of the U.S. District Court for the Southern District of New York indicated that R... 
Printer Friendly Version
06/01/15Merus appoints Mark Iwicki as President of the Supervisory Board
Utrecht, The Netherlands, June 1, 2015 — Merus B.V., a leader in developing best-in-class bispecific antibody therapeutics to treat cancer patients, today announced that Mark Iwicki has been appointed as President of its Supervisory Board.“We welcome Mark as an instrumental addition to our Supervisory Board,” said Ton Logtenberg, Merus’ CEO.  “Mark is a senior healthcare executive with a diverse and extensive background in commercialization, R&D and general management with a proven... 
Printer Friendly Version
04/20/15Merus and Selexis receive a € 2.1 million grant for single cell line manufacturing of a bispecific antibody combination to treat colorectal cancer
Utrecht, The Netherlands, May 20, 2015 — Merus B.V., a leader in developing best-in-class bispecific antibody therapeutics to treat cancer patients, and Selexis SA, a serial innovation company with proven technologies for biologics drug discovery and Research Cell Bank (RCB) development, today announced the award of the EUREKA Eurostars grant “BiSECT” with a total budget of €2.1 million to develop bispecific antibody combination products for the treatment of colorectal cancer.In the program... 
Printer Friendly Version
04/08/15Merus reaches pivotal milestone in bispecific antibody collaboration with ONO PHARMACEUTICAL CO., LTD.
– Successful product lead identification underscores the strength of Merus’ platform in delivering human, full-length IgG bispecific antibodies –Utrecht, The Netherlands, 8th April 2015 – Merus B.V., a leader in developing best-in-class bispecific antibody therapeutics, announced today that it has reached a preclinical milestone in a bispecific antibody research and license collaboration with ONO PHARMACEUTICAL CO., LTD. (Osaka, Japan, ”ONO”) triggering a payment. The milestone is for achieving ... 
Printer Friendly Version
02/04/15Merus starts Phase I/II clinical trial for MCLA-128, an ADCC-enhanced bispecific antibody for solid tumors
– First patient dosed in trial with potent bispecific antibody overcoming resistance to HER2-targeted therapies –Utrecht, The Netherlands, February 4, 2015 — Merus B.V., a leader in developing best-in-class bispecific antibody therapeutics to treat cancer patients, today announced the initiation of a phase I/II clinical study of MCLA-128 for the treatment of solid tumors. MCLA-128 is an ADCC-enhanced, full-length IgG bispecific antibody that simultaneously targets the growth factor receptors HER... 
Printer Friendly Version
01/05/15After US court ruling, Merus reaffirms freedom to operate for its MeMo® transgenic mouse for therapeutic human antibodies
Posted on 5 January, 2015 Merus B.V., a leader in developing best-in-class antibody therapeutics to treat cancer patients, today announced a series of pivotal events in its litigation with Regeneron Pharmaceuticals Inc. Previously, Regeneron sued Merus accusing it of infringing U.S. Patent No. 8,502,018 (‘018 patent’) directed to a particular method of making a genetically modified mouse, which Regeneron asserted was useful to produce therapeutic antibodies.Merus argued that Regeneron had i... 
Printer Friendly Version

RSS FeedsFinancial Tear SheetE-mail PagePrint PageE-mail Alerts